Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity
- 29 October 2012
- journal article
- Published by Wiley in Molecular Oncology
- Vol. 7 (3) , 308-322
Abstract
Cancer cells may use PARP enzymes and Homologous Recombination to repair single and double strand breaks caused by genotoxic insults. In this study, the PARP‐1 inhibitor Rucaparib was utilized to increase the sensitivity to chemoradiotherapy treatment in BRCA‐2‐deficient and ‐proficient pancreatic cancer cells. We used the pancreatic cancer cell lines, Capan‐1 with mutated BRCA‐2 and Panc‐1, AsPC‐1 and MiaPaCa‐2 with BRCA‐1/2 wild type. Cells were treated with Rucaparib and/or radiotherapy (4–10 Gy) plus Gemcitabine then the capability to proliferate was evaluated by colony formation, cell counting and MTT assays. Flow cytometry, immunocytochemistry and western blotting were utilized to assess cell response to Rucaparib plus irradiation. The antitumour effectiveness of combining the PARP‐1 inhibitor before, together and after radiotherapy evidenced the first as the optimal schedule in blocking cell growth. Pre‐exposure to Rucaparib increased the cytotoxicity of Gemcitabine plus radiotherapy by heavily inducing the accumulation of cells in G2/M phase, impairing mitosis and finally inducing apoptosis and authophagy. The upregulation of p‐Akt and downregulation of p53 were evidenced in MiaPaCa‐2 which displayed replication stress features. For the first time, the rationale of using a PARP inhibitor as chemoradiosensitizer in pancreatic cancer models has been hypothesized and demonstrated.Keywords
This publication has 37 references indexed in Scilit:
- The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in MiceMolecular Cancer Therapeutics, 2011
- NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699Oncogene, 2011
- Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancerBritish Journal of Cancer, 2011
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast CancerNew England Journal of Medicine, 2011
- Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinomaTherapeutic Advances in Medical Oncology, 2010
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection PercentagesPLOS Medicine, 2010
- Novel therapeutics in combination with radiotherapy to improve cancer treatment: Rationale, mechanisms of action and clinical perspectiveDrug Resistance Updates, 2010
- Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?Clinical Cancer Research, 2009
- Inhibition of serine/threonine phosphatase PP2A enhances cancer chemotherapy by blocking DNA damage induced defense mechanismsProceedings of the National Academy of Sciences, 2009
- Primary resection versus neoadjuvant chemoradiation followed by resection for locally resectable or potentially resectable pancreatic carcinoma without distant metastasis. A multi-centre prospectively randomised phase II-study of the Interdisciplinary Working Group Gastrointestinal Tumours (AIO, ARO, and CAO)BMC Cancer, 2007